Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
AUTL 
Autolus Therapeutics Ltd (AUTL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: AUTL (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $9.62
1 Year Target Price $9.62
| 8 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 24.35% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 367.27M USD | Price to earnings Ratio - | 1Y Target Price 9.62 |
Price to earnings Ratio - | 1Y Target Price 9.62 | ||
Volume (30-day avg) 10 | Beta 1.87 | 52 Weeks Range 1.10 - 5.00 | Updated Date 09/14/2025 |
52 Weeks Range 1.10 - 5.00 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.87 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -292.58% |
Management Effectiveness
Return on Assets (TTM) -21.43% | Return on Equity (TTM) -52.11% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -22468853 | Price to Sales(TTM) 12.27 |
Enterprise Value -22468853 | Price to Sales(TTM) 12.27 | ||
Enterprise Value to Revenue 34.98 | Enterprise Value to EBITDA 0.03 | Shares Outstanding 266140992 | Shares Floating 118518093 |
Shares Outstanding 266140992 | Shares Floating 118518093 | ||
Percent Insiders 18.09 | Percent Institutions 84.09 |
Upturn AI SWOT
Autolus Therapeutics Ltd
Company Overview
History and Background
Autolus Therapeutics Ltd was founded in 2014. It's a biopharmaceutical company focused on developing next-generation, programmed T cell therapies for the treatment of cancer.
Core Business Areas
- T-Cell Therapy Development: Autolus focuses on developing and commercializing programmed T-cell therapies, specifically CAR T-cells, for cancer treatment.
Leadership and Structure
Dr. Christian Itin is the current CEO. The company has a typical biotech structure with research, development, clinical, and commercial teams.
Top Products and Market Share
Key Offerings
- Obe-cel (AUTO3): Obe-cel (AUTO3) is Autolus' lead program, a CAR T-cell therapy targeting CD19+ B-cell malignancies, including adult ALL and DLBCL. It is currently in Phase 2 clinical trials. Competitors include Novartis (Kymriah) and Gilead (Yescarta).
Market Dynamics
Industry Overview
The CAR T-cell therapy market is rapidly growing, driven by the success of initial therapies and ongoing innovation. It's a competitive landscape with high barriers to entry due to the complexity of manufacturing and regulatory requirements.
Positioning
Autolus is positioned as a next-generation CAR T-cell therapy developer, focusing on overcoming limitations of existing therapies, such as toxicity and relapse rates. They are targeting a niche within the broader CAR T-cell market.
Total Addressable Market (TAM)
The TAM for CAR T-cell therapy is projected to reach billions of dollars annually. Autolus aims to capture a significant portion of this market with its obe-cel product if approved.
Upturn SWOT Analysis
Strengths
- Novel CAR T-cell design
- Strong preclinical data
- Experienced management team
Weaknesses
- Reliance on single product (obe-cel)
- High cash burn rate
- Clinical trial risks
Opportunities
- Potential for accelerated approval pathways
- Expansion into new indications
- Partnerships with larger pharmaceutical companies
Threats
- Clinical trial failures
- Competition from established CAR T-cell therapies
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- NVS
- GILD
- BMY
Competitive Landscape
Autolus faces intense competition from established players with approved CAR T-cell therapies. Its competitive advantage lies in its novel CAR T-cell design and potential for improved safety and efficacy.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is dependent on clinical advancements and strategic partnerships, as Autolus does not have product sales yet.
Future Projections: Future projections are based on successful clinical trials and regulatory approvals for obe-cel. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include ongoing Phase 2 clinical trials for obe-cel and exploration of new CAR T-cell targets.
Summary
Autolus Therapeutics is a clinical-stage biopharmaceutical company with a promising CAR T-cell therapy candidate, obe-cel. While the company faces significant clinical trial and financial risks, its innovative technology and experienced management team provide a foundation for potential success. Successful clinical trial outcomes and strategic partnerships will be critical for Autolus to compete in the crowded CAR T-cell therapy market. Their current dependence on Obe-cel can be risky and needs to be addressed.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Market share data are approximate and based on publicly available information.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Autolus Therapeutics Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2018-06-22 | CEO & Director Dr. Christian Martin Itin Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 647 | Website https://www.autolus.com |
Full time employees 647 | Website https://www.autolus.com | ||
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in United Kingdom and internationally. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.